United Kingdom

People: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

17 Jun 2019
Change (% chg)

$0.03 (+0.85%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Nichols, Williams 

Dr. Williams Garrett Nichols, M.D. M.S. is Chief Medical Officer of the Company. Prior to joining the Company, Dr. Nichols had been employed by ViiV Healthcare since April 2014, where he was the Head of Global Development. Prior to his tenure at ViiV, Dr. Nichols spent ten years at GlaxoSmithKline from August 2004 to April 2014 leading multiple global antiviral programs in the United States and Europe, including the development and regulatory submissions to the FDA and EMA for the approval of Tivicay and the recent FDA approval of Triumeq. Drp, 2001 to 2004, Dr. Nichols was a member of the faculty at the Fred Hutchinson Cancer Research Center in Seattle, WA, where he was the principal investigator on NIH-funded grants exploring the prevention and treatment of CMV and respiratory virus infections in HCT recipients. Dr. Nichols received his M.D. from Duke University and earned an M.S. in Epidemiology from the University of Washington, where he completed a Fellowship in Infectious Diseases.

Basic Compensation

Total Annual Compensation, USD 174,251
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,470,480
Fiscal Year Total, USD 1,644,730

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --